- Home
- OABI vs SDHY Comparison
OABI vs SDHY Comparison
Compare OABI & SDHY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OABI
- SDHY
- Stock Information
- Founded
- OABI 2012
- SDHY 2020
- Country
- OABI United States
- SDHY United States
- Employees
- OABI N/A
- SDHY N/A
- Industry
- OABI Biotechnology: Pharmaceutical Preparations
- SDHY Finance/Investors Services
- Sector
- OABI Health Care
- SDHY Finance
- Exchange
- OABI Nasdaq
- SDHY Nasdaq
- Market Cap
- OABI 490.1M
- SDHY 405.6M
- IPO Year
- OABI N/A
- SDHY N/A
- Fundamental
- Price
- OABI $3.50
- SDHY $16.24
- Analyst Decision
- OABI Strong Buy
- SDHY
- Analyst Count
- OABI 4
- SDHY 0
- Target Price
- OABI $9.00
- SDHY N/A
- AVG Volume (30 Days)
- OABI 484.9K
- SDHY 94.0K
- Earning Date
- OABI 11-12-2024
- SDHY 01-01-0001
- Dividend Yield
- OABI N/A
- SDHY 8.46%
- EPS Growth
- OABI N/A
- SDHY N/A
- EPS
- OABI N/A
- SDHY 1.07
- Revenue
- OABI $20,409,000.00
- SDHY N/A
- Revenue This Year
- OABI N/A
- SDHY N/A
- Revenue Next Year
- OABI $77.16
- SDHY N/A
- P/E Ratio
- OABI N/A
- SDHY $14.31
- Revenue Growth
- OABI N/A
- SDHY N/A
- 52 Week Low
- OABI $3.43
- SDHY $13.93
- 52 Week High
- OABI $6.72
- SDHY $15.50
- Technical
- Relative Strength Index (RSI)
- OABI 32.80
- SDHY 36.32
- Support Level
- OABI $3.43
- SDHY $16.11
- Resistance Level
- OABI $4.17
- SDHY $16.60
- Average True Range (ATR)
- OABI 0.16
- SDHY 0.12
- MACD
- OABI -0.05
- SDHY -0.05
- Stochastic Oscillator
- OABI 9.46
- SDHY 22.30
About OABI OmniAb Inc.
OmniAb Inc offers therapeutic antibody discovery technologies. The company focuses on enabling the rapid development of therapeutics by pushing the frontiers of drug discovery technologies. Its technology platform is designed to enable the efficient discovery of high-quality, fully human antibodies for a wide range of diseases. The heart of the OmniAb technology platform is the Biological Intelligence of its proprietary transgenic animals, including OmniRat, OmniMouse, and OmniChicken, that have been genetically modified to generate antibodies with human sequences which are naturally optimized through in vivo affinity maturation.
About SDHY PGIM Short Duration High Yield Opportunities Fund
PGIM Short Duration High Yield Opportunities is a closed-end management investment company. The fund's investment objective is to provide total return, through a combination of current income and capital appreciation. Its seeks to achieve its objective by investing in a diversified portfolio of high yield fixed income instruments.